Sign up to get helpful information about RYSTIGGO.

US-RZ-2400098

hero image

REACH HIGHER

with RYSTIGGO*

 

for adults with GENERALIZED MYASTHENIA GRAVIS (gMG) who are anti-AChR or anti-MuSK antibody positive

Ask your doctor about RYSTIGGO

*Based on MG-ADL and QMG results at Day 43 vs placebo in the MycarinG clinical trial. Results may vary. No head-to-head trials were conducted.

VIEW RESULTS

AChR=acetylcholine receptor; MG-ADL=Myasthenia Gravis Activities of Daily Living; MuSK=muscle-specific tyrosine kinase; QMG=Quantitative Myasthenia Gravis.

Targeted gMG treatment

 

RYSTIGGO (rozanolixizumab-noli) works by targeting FcRn, a protein in your immune system which can extend the life of harmful antibodies that can cause gMG.

SEE IT IN ACTION
FcRn=Neonatal Fc receptor.

Reduction in symptoms

 

In a clinical trial, participants taking RYSTIGGO saw significant improvements in activities of daily living as measured by MG-ADL by the end of Week 6.

VIEW TRIAL RESULTS
As determined by improvement from baseline on Day 43 of the study; −3.4 points in the RYSTIGGO-treated group (133 people) vs −0.8 in the placebo group (67 people).
Individual results may vary, and not all people will experience improvements. MG‑ADL=Myasthenia Gravis Activities of Daily Living.

Improvement by the end of Week 6

 

RYSTIGGO improved MG-ADL scores by the end of the 6-week treatment period.

VIEW THE DATA
72% (46/64) of the 7 mg/kg group and 69% (43/62) of the 10 mg/kg group responded to treatment by Day 43, compared with 31% (20/64) of the placebo group.
FcRn=Neonatal Fc receptor.
As determined by improvement from baseline on Day 43 of the study; −3.4 points in the RYSTIGGO-treated group (133 people) vs −0.8 in the placebo group (67 people).
Individual results may vary, and not all people will experience improvements. MG‑ADL=Myasthenia Gravis Activities of Daily Living.
72% (46/64) of the 7 mg/kg group and 69% (43/62) of the 10 mg/kg group responded to treatment by Day 43, compared with 31% (20/64) of the placebo group.
MuSK

The first FDA-approved treatment for

anti-MuSK antibody-positive gMG

LEARN ABOUT ANTI-MuSK gMG
Infusion in about 15 minutes

Administered in minutes

Once prepared by a healthcare professional, RYSTIGGO subcutaneous (under the surface of the skin) infusions may be completed in about 15 minutes.

WHAT TO EXPECT

Infusion time may vary.

ONWARD™ personalized support designed to move you forward.

Here for you throughout your treatment

ONWARD® provides personalized support, including help to understand coverage and financial options, tools to help you track symptoms, and guidance when starting and continuing treatment.

LEARN MORE

ONWARD is provided as a service of UCB and is intended to support the appropriate use of UCB medicines. ONWARD may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.